{"groups":[{"description":"Participants received pembrolizumab 2 mg/kg intravenously (IV) over 30 minutes every 3 weeks (Q3W) for up to 2 years. Qualified participants who received the first course of pembrolizumab 2 mg/kg Q3W for up to 2 years, but experienced disease progression, initiated a second course of pembrolizumab at the investigator's discretion, at 200 mg IV Q3W for up to 1 year.","id":"FG000","title":"Pembrolizumab 2 mg/kg"},{"description":"Participants received pembrolizumab 10 mg/kg IV over 30 minutes Q3W for up to 2 years. Qualified participants who received the first course of pembrolizumab 10 mg/kg Q3W for up to 2 years, but experienced disease progression, initiated a second course of pembrolizumab at the investigator's discretion, at 200 mg IV Q3W for up to 1 year.","id":"FG001","title":"Pembrolizumab 10 mg/kg"},{"description":"Participants received docetaxel 75 mg/m\\^2 IV over 1 hour Q3W for up to 2 years. Qualified participants who received docetaxel 75 mg/m\\^2 Q3W for up to 2 years, but experienced disease progression, switched over to pembrolizumab, at the investigator's discretion, at 200 mg IV Q3W for up to 2 years.","id":"FG002","title":"Docetaxel 75 mg/m^2"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"17"},{"groupId":"FG002","numSubjects":"18"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"103"},{"groupId":"FG001","numSubjects":"78"},{"groupId":"FG002","numSubjects":"59"}],"type":"Clinical Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"40"},{"groupId":"FG001","numSubjects":"43"},{"groupId":"FG002","numSubjects":"47"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"16"},{"groupId":"FG002","numSubjects":"9"}],"type":"Excluded Medication"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"8"},{"groupId":"FG002","numSubjects":"12"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"}],"type":"Screen Failure"},{"reasons":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"21"},{"groupId":"FG002","numSubjects":"53"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"Sponsor Decision"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"345"},{"groupId":"FG001","numSubjects":"346"},{"groupId":"FG002","numSubjects":"343"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"339"},{"groupId":"FG001","numSubjects":"343"},{"groupId":"FG002","numSubjects":"309"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"0"}],"type":"Received Second Course of Pembrolizumab"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"8"}],"type":"Switched Over to Pembrolizumab"},{"achievements":[{"groupId":"FG000","numSubjects":"142"},{"groupId":"FG001","numSubjects":"159"},{"groupId":"FG002","numSubjects":"143"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"203"},{"groupId":"FG001","numSubjects":"187"},{"groupId":"FG002","numSubjects":"200"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Per protocol, response or progression during the second and switch over pembrolizumab courses was not counted towards efficacy outcome measures, and adverse events during the second and switch over pembrolizumab courses were not counted towards safety outcome measures.\n\nFinal analyses for all primary and secondary outcome measures was done at the protocol-specified cutoff of 30-Sep-2015.","recruitmentDetails":"Participants who had non-small cell lung cancer (NSCLC) and whose tumors were assessed as being programmed cell death ligand 1 (PD-L1) positive were recruited for this study."}